Author

Lenushka Maharaj

Observed name: Maharaj, Lenushka

Institutions: Queen Mary University of London, Barts Cancer Institute, University College London

Observed institutions: St Bartholomew's Hospital, University of Auckland, Queen Mary University of London, The University of Western Australia, Christie's, Cancer Research UK, Southampton General Hospital, The Christie Hospital, Barts Cancer Institute, Takeda Oncology (United States), University College London

OpenAlex ID: A5113537997

Mechanisms of cytotoxicity and antitumor activity of gold(I) phosphine complexes: the possible role of mitochondria

2002 · Mark J McKeage, Lenushka Maharaj, et al. · Coordination Chemistry Reviews · 246

In vitro antitumour and hepatotoxicity profiles of Au(I) and Ag(I) bidentate pyridyl phosphine complexes and relationships to cellular uptake

2007 · Johnson J. Liu, Peter Galettis, et al. · Journal of Inorganic Biochemistry · 179

Bortezomib Therapy in Patients With Relapsed or Refractory Lymphoma: Potential Correlation of In Vitro Sensitivity and Tumor Necrosis Factor Alpha Response With Clinical Activity

2006 · Sandra J. Strauss, Lenushka Maharaj, et al. · Journal of Clinical Oncology · 170

PDF

GCS-100, a novel galectin-3 antagonist, modulates MCL-1, NOXA, and cell cycle to induce myeloma cell death

2010 · Matthew J. Streetly, Lenushka Maharaj, et al. · Blood · 133

PDF

P110α-mediated constitutive PI3K signaling limits the efficacy of p110δ-selective inhibition in mantle cell lymphoma, particularly with multiple relapse

2013 · Sunil Iyengar, Andrew Clear, et al. · Blood · 123

The Proteasome Inhibitor Bortezomib Acts Independently of p53 and Induces Cell Death via Apoptosis and Mitotic Catastrophe in B-Cell Lymphoma Cell Lines

2007 · Sandra J. Strauss, Karen Higginbottom, et al. · Cancer Research · 112

PDF

Methylseleninic acid inhibits HDAC activity in diffuse large B-cell lymphoma cell lines

2011 · Shireen Kassam, Heidi Goenaga-Infante, et al. · Cancer Chemotherapy and Pharmacology · 39

Phase II Clinical Study of Bortezomib (VELCADE®) in Patients (pts) with Relapsed / Refractory Non-Hodgkin’s Lymphoma (NHL) and Hodgkin’s Disease (HD).

2004 · Sandra J. Strauss, Lenushka Maharaj, et al. · Blood · 19

Schedule dependent cytotoxicity of bortezomib and melphalan in multiple myeloma

2012 · Rakesh Popat, Lenushka Maharaj, et al. · British Journal of Haematology · 6

PDF

PI3K Inhibition with GDC-0941 Has Greater Efficacy Compared to p110δ-Selective Inhibition with CAL-101 in Mantle Cell Lymphoma and May Be Particularly Advantageous in Multiply Relapsed Patients

2011 · Sunil Iyengar, Andrew J. Clear, et al. · Blood · 4

The histone deacetylase inhibitor UCL 67022 has potent activity in multiple myeloma and non‐ H odgkin lymphoma pre‐clinical models

2013 · Lenushka Maharaj, Charles M. Marson, et al. · British Journal of Haematology · 3

PDF

IL-6, IL-8 and VEGF Neutralisation Restores Drug Sensitivity to Conventional and Novel Treatment Combinations in a Multiple Myeloma Bone Marrow Micro-Environment Model.

2012 · Lenushka Maharaj, Rakesh Popat, et al. · Blood · 3

A Novel Heat Shock Protein (HSP) 90 Inhibitor KW-2478 shows Activity in B-Cell Malignancies in Vitro and in Vivo.

2008 · Simone Juliger, Takayuki Nakashima, et al. · Blood · 3

The Novel HDAC Inhibitor UCL67022 Is Highly Potent in Multiple Myeloma and Non-Hodgkin’s Lymphoma and Is Enhanced by Bortezomib.

2006 · Lenushka Maharaj, Rakesh Popat, et al. · Blood · 3

Mantle Cell and Follicular Lymphoma Samples Demonstrate Differing Sensitivity to Bortezomib in a Primary Culture System.

2004 · Lenushka Maharaj, Sandra J. Strauss, et al. · Blood · 3

Increased Tonic PI3K Signaling Through p110α Can Limit the Efficacy of P110δ-Selective Inhibition in Mantle Cell Lymphoma, Particularly with Multiple Relapse

2012 · Sunil Iyengar, Andrew James Clear, et al. · Blood · 1

Use of in vitro primary culture models to investigate the activity of standard and novel therapies in haematological malignancies

2013 · Lenushka Maharaj

Abstract 4489: The activity of novel, potent, selective PI3K/mTOR pathway inhibitors in B-cell malignancies

2010 · Simone Jueliger, Lenushka Maharaj, et al. · Cancer Research

Abstract 3651: Methylseleninic acid (MSA) is an HDAC inhibitor and suppresses VEGF production in lymphoma cell lines

2010 · Shireen Kassam, Lenushka Maharaj, et al. · Cancer Research

GCS-100 Targets Apoptosis and Cell Cycle Regulation in Myeloma Cells.

2009 · Matthew Streetly, Lenushka Maharaj, et al. · Blood

In vitro studies of bidentate pyridyl phosphine gold(I) and silver(I) complexes as potential antitumour agents in ovarian tumor cell lines and isolated hepatocytes

2005 · Jianzhong Liu, Peter Galettis, et al. · Cancer Research

Works count: 22

Citation count: 1,047

H-index: 8

I10-index: 8